Published in Ann Rheum Dis on November 01, 2001
Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther (2010) 0.96
Effect of tumour necrosis factor-alpha receptor 1 genetic deletion on carrageenan-induced acute inflammation: a comparison with etanercept. Clin Exp Immunol (2008) 0.83
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Severe psoriasis--oral therapy with a new retinoid. Dermatologica (1978) 5.67
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol (2000) 3.62
Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol (1991) 2.89
Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med (1991) 2.66
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.85
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol (1994) 1.83
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Patterns of cytokine production in psoriatic synovium. J Rheumatol (1998) 1.72
Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum (2000) 1.65
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol (1995) 1.60
Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol (1990) 1.57
Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum (1984) 1.46
Psoriatic arthritis in psoriatic patients. Br J Rheumatol (1984) 1.40
Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol (1990) 1.30
Psoriatic arthritis. Rheum Dis Clin North Am (1998) 1.15
Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) (1989) 1.03
T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis (1998) 1.02
Psoriatic arthritis. Curr Opin Rheumatol (1992) 0.92
A multidisciplinary approach to psoriatic arthropathy. Community Nurse (1999) 0.81
A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol (1990) 0.80